TOPLINE:

Synergistic therapy combining colistin and meropenem reduced clinical failure rates in carbapenem-resistant infections and was particularly effective in Acinetobacter baumannii pneumonia cases.

METHODOLOGY:

Researchers reported the findings from a secondary analysis of a randomized, double-blind trial that assessed the impact of synergistic therapy of colistin and meropenem on carbapenem-resistant pneumonia and/or bloodstream in adults.

Overall, 407 patients (mean age, 68.0 years; 50.9% White; 63.5% men) were categorized into receiving synergistic combination therapy (n = 146) and functional monotherapy (n = 261) that included non-synergistic combination therapy and monotherapy.

Outcomes of interest were 28-day all-cause mortality, clinical failure, and microbiologic cu

See Full Page